In:
International Journal of Cancer, Wiley, Vol. 144, No. 3 ( 2019-02), p. 595-606
Abstract:
What's new? The arginine methyltransferase PRMT5 is associated with tumor progression in various cancers; however, its expression in breast cancer remains understudied. Here, the authors found that, as in prostate cancer, PRMT5 nuclear localization may have protective effects. Indeed, its expression is associated with higher patient survival. In addition, two threonine residues essential to PRMT5 enzymatic activity were identified. Interestingly, the tumor suppressor LKB1 a master kinase that regulates cell polarity, energy metabolism, and mTOR signaling phosphorylates PRMT5 on these residues, thereby decreasing the methyltransferase activity of PRMT5. These results highlight new opportunities to measure and target PRMT5 activity in breast cancer.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink